Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Avalon GloboCare Corp. (AVCO)

0.5259   -0.104 (-16.52%) 11-09 16:00
Open: 0.62 Pre. Close: 0.63
High: 0.6507 Low: 0.5202
Volume: 432,165 Market Cap: 52(M)

Technical analysis

as of: 2022-11-28 10:47:08 AM
Overall:       
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 0.71     One year: 0.87
Support: Support1: 0.37    Support2: 0.31
Resistance: Resistance1: 0.6    Resistance2: 0.74
Pivot: 0.47
Moving Average: MA(5): 0.43     MA(20): 0.47
MA(100): 0.53     MA(250): 0.63
MACD: MACD(12,26): -0.1     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 10.5     %D(3): 13.6
RSI: RSI(14): 43.2
52-week: High: 1.07  Low: 0.37
Average Vol(K): 3-Month: 197 (K)  10-Days: 446 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ AVCO ] has closed above bottom band by 30.5%. Bollinger Bands are 33.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 0.45 - 0.45 0.45 - 0.45
Low: 0.41 - 0.41 0.41 - 0.41
Close: 0.43 - 0.43 0.43 - 0.44

Company Description

Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and the People's Republic of China. The company offers medical related consulting services, including research studies, executive education, daily online executive briefings, tailored expert advisory services, and consulting and management services in the areas of immunotherapy and second opinion/referral services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells. It is also developing RNA-based FASH-CARTM cell therapy platform. In addition, the company develops avalon clinical-grade tissue-specific exosome (ACTEX); offers therapeutic and diagnostic targets utilizing QTY-code protein design technology with Massachusetts Institute of Technology (MIT), including using the QTY code protein design technology for development of a hemofiltration device to treat Cytokine Storm; and provides co-development of next generation, transposon-based, multi-target CAR-T, CAR-NK, and other immune effector cell therapeutic modalities with Arbele Limited. Further, it has strategic partnership with the University of Natural Resources and Life Sciences in Vienna and Austria to develop an S-layer vaccine that could be administered by an intranasal or oral route against SARS-CoV-2 and coronavirus that causes COVID-19 disease; and develops Avalon Cell and Avalon Rehab, as well as promotes standardization related to exosome industry. The company is headquartered in Freehold, New Jersey.

Headline News

Mon, 21 Nov 2022
John W. Keegan - The Newtown Bee

Mon, 21 Nov 2022
CHANCE, Gerald - Springfield News Sun

Fri, 18 Nov 2022
Obituary for Garland Frank Pierce of Southern Pines - Sandhill Sentinel

Thu, 17 Nov 2022
Obituary: Arthur Funk, 88, Of Stratford - Patch

Thu, 17 Nov 2022
Radio Silence to Direct John Carpenter’s ‘Escape From New York’ Reboot - Yahoo Entertainment

Wed, 09 Nov 2022
Avalon GloboCare Announces NASDAQ Ticker Symbol Change from “AVCO” to “ALBT” - GlobeNewswire

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Real Estate
Industry:  Real Estate Services
Shares Out. 99 (M)
Shares Float 38 (M)
% Held by Insiders 66.4 (%)
% Held by Institutions 0.9 (%)
Shares Short 447 (K)
Shares Short P.Month 495 (K)

Stock Financials

EPS -0.11
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -581.7
Return on Assets (ttm) -47.9
Return on Equity (ttm) -497.1
Qtrly Rev. Growth 5.3
Gross Profit (p.s.) 0
Sales Per Share 0.01
EBITDA (p.s.) -0.08
Qtrly Earnings Growth 0
Operating Cash Flow -5 (M)
Levered Free Cash Flow 1 (M)

Stock Valuations

PE Ratio -4.12
PEG Ratio 0
Price to Book value 0
Price to Sales 30.61
Price to Cash Flow -8.14

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date 2016-10-17
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.